Davion Healthcare (Nasdaq: DAVI) expects its ordinary shares to begin trading on the Nasdaq Global Market on 22 October 2026. Glenn Williams will become Chief Executive Officer and Jeremy North Chief Operating Officer when trading begins. Current CEO Jack Kaye will become Chairman, while Sir Eric Peacock will remain a Non-Executive Director after stepping down as Chairman.
A new Operational Directorate, led by Williams, will manage daily operations, commercialisation, distribution and acquisition execution, with the Board retaining oversight. Davion is developing international manufacturing and distribution capabilities and pursuing complementary healthcare acquisitions. It recently established Davion Healthcare Finance and launched a £30 million five-year senior secured bond. Its BreastCheck at-home breast health screening test is FDA-registered but is not a replacement for mammography or clinical diagnosis.